Safety outcomes at month 12
| AE, n (%) | Patients (n=586) |
| Any AE | 118 (20.1) |
| Any TEAE | 118 (20.1) |
| Any treatment-related TEAE | 11 (1.9) |
| Any ocular TEAE (study eye) | 8 (1.2) |
| Most common ocular AE (>0.5%) | |
| Vitreous floaters | 11 (1.9) |
| Lacrimation increased | 6 (1.0) |
| Eye pain | 5 (0.9) |
| Photophobia | 4 (0.7) |
| Dry eye | 4 (0.7) |
| Conjunctivitis | 4 (0.7) |
| Eye irritation | 3 (0.5) |
| Conjunctival haemorrhage | 3 (0.5) |
| Eye pruritus | 3 (0.5) |
| Vision blurred | 3 (0.5) |
| Visual impairment | 3 (0.5) |
| Endophthalmitis | 0 (0.0) |
| Any SAE (>0.3%) | 23 (3.9) |
| Cancer | 3 (0.5) |
| Confusional state/disorientation | 3 (0.5) |
| Ischaemic stroke | 3 (0.5) |
| Any nonocular TEAE | |
| Most common nonocular AE (>0.5%) | |
| Product use issue | 17 (2.9) |
| Cardiac failure | 5 (0.9) |
| Bronchitis | 5 (0.9) |
| Drug hypersensitivity | 5 (0.9) |
| Injection site pain | 4 (0.7) |
| Malaise | 4 (0.7) |
| Falls | 4 (0.7) |
| Gastroenteritis | 3 (0.5) |
| Pneumonia | 3 (0.5) |
| Vertigo | 3 (0.5) |
| Back pain | 3 (0.5) |
| Osteoarthritis | 3 (0.5) |
| Ischaemic stroke | 3 (0.5) |
| Syncope | 3 (0.5) |
| Death (not treatment related) | |
| Sudden | 3 (0.5) |
| Secondary to AE | 6 (1.0) |
| Any TEAE leading to discontinuation | 6 (1.0) |
| Transient ischaemic attack | 1 (0.2) |
| Any treatment-related TEAE leading to discontinuation | 0 |
AE, adverse event; SAE, serious AE; TEAE, treatment-emergent AE.